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ABSTRACT
The national blood transfusion policies have been changed significantly in recent years in Turkey. The 
purpose of this study was to determine the prevalence of HBV, HCV, and HIV in blood donors at the 
Red Crescent Center in Istanbul and to evaluate the effect of changes in the national blood transfu-
sion policies on the prevalence of these infections. The screening results of 72695 blood donations at 
the Red Crescent Center in Istanbul between January and December 2007 were evaluated retrospec-
tively. HBsAg, anti-HCV, and anti-HIV-1/2 were screened by microparticle enzyme immunoassay 
(MEIA) method. Samples found to be positive for anti-HIV 1/2 and anti-HCV were confirmed by 
Inno-Lia HCV Ab III and Inno-Lia HIV I/II Score, respectively. The seropositivity rates for HBsAg, 
anti-HCV, and anti-HIV-1/2 were determined as 1.76%, 0.07%, and 0.008%, respectively. Compared 
to the previously published data from Red Crescent Centers in Turkey, it was found that HBV and 
HCV seroprevalances decreased and HIV seroprevalance increased in recent years. In conclusion, 
we believe that the drop in HBV and HCV prevalence rates are likely multifactorial and may have 
resulted from more diligent donor questioning upon screening, a higher level of public awareness 
on viral hepatitis as well as the expansion of HBV vaccination coverage in Turkey. Another factor to 
contribute to the decreased prevalence of HCV stems from the use of more sensitive confirmation 
testing on all reactive results, thereby eliminating a fair amount of false positive cases. Despite similar 
transmission routes, the increase in HIV prevalence in contrast to HBV and HCV may be linked to 
the increase in AIDS cases in Turkey in recent years.
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INTRODUCTION
A number of viruses, bacteria and parasites can 
be transmitted through blood or blood prod-
ucts. Amongst these, the hepatitis B virus (HBV), 
hepatitis C virus (HCV), and the human immu-
nodeficiency virus (HIV) are mandatorily tested 
on blood donors worldwide due to the potential 
serious chronic clinical sequelae associated with 
these readily transmitted agents.1,2 
Nevertheless, since donor history question-
ing is performed more diligently and due to 
the advances in screening techniques, the risk 
of transmission has decreased considerably.3 
However, small risks of infection transmission 
persist due to several factors such as genetic 
variations of infectious agents, presence of an 
immunologically silent carriage, laboratory er-
rors, and variations in the window period of an 
infectious agent as well as limitations in screen-
ing testing methodology.2,4
As mandated by the Turkish legal system, 
it is a law to screen all voluntary blood do-
nors for HBV, HCV, HIV-1/2, and Trepone-
ma palladium. The Blood and Blood Prod-
ucts Act, accepted by the Turkish parliament 
in 2007, has dropped the rate of transfusion 
mediated infections by raising the stan-
dards of donor screening through improved 
history questioning and risk factor assess-
ments. Intense campaigns for public aware-
ness against HBV, HCV, and HIV have also 
been launched. This study is aimed at pre-
senting the effects of the new Turkish leg-
islature and particularly looks at how these 
policies have brought upon changes in the 
prevalence rates of transfusion mediated 
infections in the city of Istanbul where ap-
proximately one fourth of the entire Turk-
ish population resides. 
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Seroprevalence of HBV, HCV, and HIV in blood donors
MATERIAL AND METHODS
During the period of January to December 2007, the HBV, 
HCV, and HIV-1/2 screening test results of blood donors and 
the confirmatory test results of HCV and HIV-1/2 seropositive 
donors were retrospectively obtained from laboratory records.
HBsAg, anti-HCV, and anti-HIV-1/2 screening tests were 
performed on the automatic EIA instrument (Davinci, Biomer-
ieux) with the microparticle enzyme immunoassay (MEIA) 
method using the micro-Elisa kit (Hepanostika, HBsAg Uni-
Form II, bioMerieux, NL) based on the single step “sandwich” 
principle for HBsAg, the 4th generation EIA kit (Innotest, HCV 
Ab IV, Innogenetics N.V. Belgium) containing CORE, NS3, 
NS4, and NS5 antigens of HCV for anti-HCV, and the micro-
Elisa kit (Vironostika, HIV Uni-Form II Ag/Ab, NL) based on 
the single step “sandwich” principle for anti-HIV-1/2. 
In the methods used, the signal-to-cutoff (S/CO) ratio ≥ 1 
for HBsAg, anti-HCV, and anti-HIV were considered as reac-
tive. Initial S/CO ratios in the range of 0.70-0.99 for HCV and 
0.75-0.99 for HIV were considered as being in the grey zone. 
There was no grey zone establishment for HBV. Reactive sam-
ples or samples in grey zone in the screening tests were retested 
using the same immunoassay. If one or both of the retested 
specimens reacted then, it was referred as repeatedly reactive 
and was considered screening tests positive.
For samples that showed repeatedly reactive with HBsAg 
EIA, no confirmatory tests were carried out and those repeatedly 
reactive samples were interpreted as positive. Repeatedly reactive 
samples in the anti-HCV EIA testing were confirmed using the 
3rd generation Line Immune Assay (LIA) test method (INNO-
LIA, HCV Score, Innogenetics, Belgium), which included the C1, 
C2, E2, NS3, NS4, NS5 regions of the HCV genome. The anti-
HIV EIA repeatedly reactive results were confirmed by the LIA 
kit (INNO-LIA, HIV I/II Score, Innogenetics, Belgium) contain-
ing HIV 1.2 and HIV 1 group O antigens. LIA test results were 
evaluated according to the recommendations of the assay manu-
facturer company and results for both anti-HCV and anti-HIV 
were interpreted as positive, indeterminate or negative.
Statistical analysis
All statistical analyses were carried out with computer software 
(SPSS; Version 10.0; SPSS, Inc; Chicago, IL). Means, coefficients 
of variation, standard deviations and confidence intervals were 
determined. Statistical studies were evaluated using Pearson 
chi-square and Fisher’s exact test. A p-value < 0.05 was consid-
ered to be statistically significant.
RESULTS
Screening test results
During the period of January to December 2007, EIA screen-
ing testing was performed on 72695 blood donors at the Red 
Crescent Center in Istanbul, Turkey. At baseline screening 
testing, 1377 HBsAg, 393 anti-HCV, and 198 anti-HIV posi-
tive results were detected (Table 1). Baseline tests revealed 
that 130 of the anti-HCV positive samples (33.1%) and 79 
of the anti-HIV samples (39.9%) were within the grey zone 
index values (Table 1). For samples that fell within the grey 
zone index value from the initial testing, we determined the 
rate of repeated reactivity as 80.8% (105/130) for anti-HCV 
and 65.8% (52/79) for anti-HIV, whereas those above the 
positive limit index value were determined as 97% (255/263) 
and 59.7% (71/119), respectively. When the total sample size 
was considered, the repeatedly reactive rate for HBsAg, anti-
HCV, and anti-HIV was found to be 92.8% (1278/1377), 
91.6% (360/393), and 62.1% (123/198) respectively (Table 
1). Based on these results, the overall seropositivity rate for 
the initial test results were 1.89% for HBsAg, 0.54% for anti-
HCV, and 0.27% for anti-HIV. Based upon repeated reac-
tive test results, the seropositivity rate dropped to 1.76% 
for HBsAg, 0.50% for anti-HCV, and 0.17% for anti-HIV. 
When repeat reactive samples were sorted out and the rate 
of true positivity was determined, it was found that 99 of the 
1377 HBsAg results (7.2%), 33 of the 393 anti-HCV results 
(8.4%), and 75 of the 198 anti-HIV results (37.9%) were 
biologically false positive (BFP) (Table 2). 
Table 1. HBs Ag, anti-HCV, anti-HIV EIA screening test results and repeating reactivity rate
              Number of  initially    Number of repeatedly reactive samples 
    reactive samples 
   Grey zone Positive Total Grey zone Positive limit index Total 
   limit index 
   N N N N (%) N (%) N (%)
  Number tested 
 HBsAg 72,695 - 1,377 1,377 - 1,278 (92.8) 1,278 (92.8)
 Anti-HCV 72,695 130 263 393 105 (80.8) 255 (97) 360 (91.6)
 Anti-HIV 72,695 79 119 198 52 (65.8) 71 (59.7) 123 (62.1)
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Confirmatory test results 
HBsAg
For the evaluation of the HBsAg results, samples showing 
repeating reactivity with EIA were accepted as positive re-
sults and no further confirmatory tests were carried out. As 
a result, our study revealed the HBsAg seroprevalence to be 
1.76% among blood donors. 
HCV
In 360 serum samples with positive anti-HCV screening test 
results (29.2% s/co = 0.70-1; 70.8% s/co ≥ 1), 54 (15%) posi-
tive, 217 (60.3%) negative, 89 (24.7%) indeterminate results 
were obtained by LIA. When indeterminate results were ex-
cluded, the anti-HCV seroprevalence was 0.07% (54/72695). 
Out of the 54 LIA positive samples, 2 were from the of 
(grey zone) 0.70-0.99 and 52 were from samples that had a 
S/CO value of ≥ 1. In other words, for initial EIA test sam-
ples that were considered positive but within the grey zone 
(S/CO value between 0.70 and 1.0), the rate of confirmation 
upon LIA testing was only 2%, whereas samples with an ini-
tial S/CO index value >1% had a confirmation test positive 
rate of 20.4%. The difference in their rates of LIA confir-
mation positivity was statistically significant (p < 0.0001). 
Thus, samples within grey zone index values had signifi-
cantly higher negative outcome rates as determined by LIA 
confirmation, compared to samples with s/co rates above 
the positive threshold value (p < 0.0001). However, among 
indeterminate results, no difference was found between the 
s/co rates in the grey zone and those with positive threshold 
values (p > 0.05) upon LIA testing (Table 3). When indeter-
minate results were excluded, 60.3% of the anti-HCV EIA 
positive results were concluded to be BFP. 
HIV
In 123 serum samples with positive anti-HIV screening test 
results (42.3% s/co = 0.75-1; 57.7% s/co ≥ 1), 8 (6.5%) posi-
tive and 115 (93.5%) negative results were obtained using 
LIA. According to results verified by LIA, the HIV seropreva-
lence among our blood donors was 0.008% (6/72695). 
All samples with grey zone s/co rates had negative results 
with LIA, compared to 8 positive and 63 negative results in 
samples with s/co ≥1 (p = 0.020), (Table 4). When indeter-
minate results were excluded, 95.1% of the anti-HIV EIA 
positive results were concluded to be BFP. 
Table 2. The biologically false positive rate in the first tests, after results with repeating reactivity in screening 
tests were accepted as true positive
 Initially reactive samples Repeatedly reactive samples Biologically false positive  
 N (%) N (%) N (%)
HBsAg* 1,377 (1.89) 1,278 (1.76) 99 (% 7.2)
Anti-HCV 393 (0.54) 360 (0.50) 33 (% 8.4)
Anti-HIV 198 (0.27) 123 (0.17) 75 (% 37.9
Table 3. Confirmatory results of anti-HCV reactive results with LIA
  Anti-HCV confirmatory test (lIA) results
 Positive Negative Indeterminate 
  N % N % N %
Grey zone (105) 2 (1.9) 80 (76.2) 23 (21.9)
Positive index (255) 52 (20.4) 137 (53.7) 66 (25.9)
Total (360) 54 (15.0) 217 (60.3) 89 (24.7)
p  < 0.0001 < 0.0001 > 0.05
Table 4. Confirmatory results of anti-HIV reactive results with LIA
  Anti-HIV confirmatory test (lIA) results
 Positive Negative Indeterminate 
  N % N % N %
Grey zone (105) 0 52 (100) 0
Positive index (255) 6 (8.5) 64 (91.5) 1
Total (360) 6 (4.9) 117 (95.1) 1
p  0.038 0.038
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DISCUSSION
This study contains important results showing that, com-
pared to previous years, the infection rates have decreased 
among blood donors and that transfusions are being car-
ried out more safely as a result of vaccination and training 
campaigns launched in Turkey’s largest metropolitan city of 
Istanbul, all of which have been the results of the private sec-
tor efforts as well as governmental agencies under the direc-
tive of the Turkish Ministry of Health.
In screening tests performed on the general public in 
Turkey, the incidence of HBsAg positivity has ranged be-
tween 1.7-21%.5 According to studies conducted by various 
blood bank centers, HBsAg positivity amongst blood donors 
was 5.2% during the periods between 1985 and 1999, which 
then decreased to 2.97% between 2000 and 2003.6 HBsAg 
positivity among blood donors and the general population 
has been gradually declining over the years. Reasons for this 
drop have been attributed to heightened public knowledge 
about HBV as well as the expansion and implementation 
of public vaccination policies.6-8 The most extensive data 
pertaining to HBV seroprevalence in blood donors is de-
rived from the Red Crescent Centres. HBV seroprevalence 
of 6,240,130 candidates giving blood at the Red Crescent 
Centres throughout Turkey in 1989-2004 was on average 
4.9%.7 In the same study, HBsAg positivity was found to be 
4.92% in 1989, 5.23% in 1991, and 2.10% in 2004. The de-
crease in Hepatitis B seroprevalence was attributed to the 
decrease in the number of military blood donors (positive 
correlation) and to the increase in voluntary donors (nega-
tive correlation).7 Based on the results of the Red Crescent 
Centers from Istanbul between 1987 and 2003, the mean 
HBsAg positivity was 4%, with a decrease in seroprevalence 
from 5% to 2.07%.8 This decrease in HBV seroprevalence 
was emphasized as being attributed to greater care taken in 
donor questioning and to the use of more sensitive screen-
ing tests from 1997 onwards.8 Our study determined HBsAg 
positivity to be 1.7%, which is 2.6 times (p < 0.05) lower 
than the HBV seroprevalence detected by the Red Crescent 
Centre’s throughout Turkey7 and 2.3 times (p < 0.05) lower 
than the results given for the city of Istanbul.8 Based on our 
results, a general trend towards a decline in HBsAg positiv-
ity in donor population was observed over the past several 
years. In addition to improved public awareness and expan-
Table 5. Biologically false positive rate in anti-HCV and anti-HIV EIA screening results according to confirmatory 
test results
 Prevalence in accordance Prevalence in accordancew Biologically false positive 
 with the screening test with the confirmatory test  
 N   (%) N   (%) N   (%) 
HCV 360 (0.50) 54 (0.07) 306 (% 85)
HIV1,2 123 (0.17) 6 (0.008) 117 (% 95)
Figure 1: Comparison of HBV, HCV and HIV seroprevalance among our blood donors with seroprevalence 
reported in the most extensively ranging studies conducted in the general Turkish population and the 
Red Crescent Centres. (*No HIV prevalence was reported at the Red Crescent Centre in Turkey results).
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sion of vaccination policies, another reason for the observed 
decline seen in our results likely stems from the use of highly 
sensitive test kits by our group upon which samples were 
accepted as “True Positive’’ only if clear cut repeat reactiv-
ity was demonstrated, thereby excluding false positives that 
would have otherwise been accepted as positive. 
In Turkey, HCV incidence in the general population 
ranges between 1-2.4%. In contrast, the ratio among blood 
donors is 0.3-1.8%.7,10 Unlike HBV, the incidence of HCV 
infection does not show significant difference between 
regions.9,10 Anti-HCV positivity in blood donations report-
ed from various centres was 0.6% between 1991 and 1999 
and 0.54% between 2000 and 2006, showing no significant 
change over the years.6 Based on the Red Crescent Center’s 
results reflecting the general population across Turkey, an-
ti-HCV seroprevalence between 1996 and 2004 was 0.38%.7 
In comparison, anti-HCV positivity for the period of 1996-
2003 was 0.5%, based on the Istanbul’s Red Crescent Center 
results.8 In our study, anti-HCV positivity among blood do-
nors was found to be 0.07%. This result is 7 times lower than 
the overall Red Crescent Centre’s results throughout Tur-
key (p < 0.05) and 5 times lower than the results in Istanbul 
(p < 0.05). If the incidence in the overall population is ac-
cepted as 1%, it can be said that, compared to the general 
public, the HCV seroprevalence of our blood donors is ap-
proximately 14 times lower. We believe that the reason for 
the results to vary to such a degree stems from the fact that 
most Turkish conducted studies report reactive screening 
results as positive without verifying anti-HCV positivity by 
confirmation testing. In comparison, in our study repeat 
reactivity was confirmed with the use of a sensitive con-
firmatory test. Our view is further supported by the fact 
that 85% of the samples determined as positive during the 
screening test were actually BFP according to the confirma-
tory test results. 
It is estimated that 33.2 million people throughout the 
world carry the HIV virus.11 Based on the data obtained from 
the Ministry of Health, as of 2006, 2544 cases of HIV/AIDS 
have been reported in Turkey.12 In 3% of these cases, the 
route of transmission was through blood and blood prod-
uct transfusions.12 Based upon data obtained from the Red 
Crescent Center between the periods of 1996 and 2003, An-
ti-HIV positivity on 1,737,943 screened donors was 0.001% 
and no significant changes were observed in this rate over 
the years.8 Based upon data obtained from the Turkish Min-
istry of Health, HIV/AIDS incidence rates between 2000 and 
2005 were 0.023%, 0.027%, 0.027%, 0.028%, 0.030%, and 
0.046%, respectively.12 Data from the Red Crescent Center 
revealed that over the past seven years, the incidence of HIV 
amongst donors remained low without an increase, while the 
incidence in the general population gradually increased over 
the years. The rate of anti-HIV positivity amongst blood 
donors from our study was 0.008%, based upon our con-
firmatory test results. From the Red Crescent Center’s data, 
it was noted that the rate of anti-HIV positivity in Istan-
bul had increased eightfold amongst screened blood donors 
(p < 0.05). This might be attributable to the fact that donor 
candidates with risk factors for HIV tend to conceal their 
condition during donor questioning out of fear of associ-
ated social labelling. 
There are however some shortcomings in our study. One 
of these is the lack of confirmation testing of our HBsAg 
results. Although the specificity of the EIA tests used during 
HBsAg screening is nearly 100%, there was a need to confirm 
the positive results with a neutralization test, particularly in 
communities with a low prevalence of Hepatitis B, such as 
voluntary blood donors.13,14 In a study recently conducted in 
Turkey, nearly 70% of the weak positive HBsAg results (with 
a S/CO ratio between 1 and 2.5) were determined to be nega-
tive (false positive) in the confirmatory neutralization tests.15 
Another study found the false positivity rate in weak positive 
samples to be significantly higher than those of the strong 
positive samples and recommended that confirmatory tests 
should only be performed on weakly positive samples.16 
Based on these results, if confirmatory testing were carried 
out in our HBsAg positive results, a part of the weak positive 
samples in particular would have had a negative result and 
the subsequent HBV prevalence among our blood donors 
would have been even lower. A further shortcoming was that 
indeterminate results for anti-HCV and anti-HIV results 
were not finalized with further testing. When anti-HCV EIA 
positive results are shown to be indeterminate upon immu-
noblot confirmatory testing, it is recommended to either 
repeat the anti-HCV EIA test or perform a HCV RNA quan-
tification for the same donor.17 Amongst blood donors, most 
indeterminate anti-HCV immunoblot results test negative 
upon repeat testing,17 however, occasionally serum samples 
that had been in the pre-seroconversion window period can 
later seroconvert to positive.18 Similarly, during the window 
period for individuals recently infected, HIV confirmatory 
testing may have an indeterminate outcome. For these cases, 
repeat HIV testing (screen with confirmation) are recom-
mended after 1-2 months.19 In low risk HIV/HCV popula-
tions, it has been hypothesized that repeat indeterminate 
results are largely due to the development of auto antibod-
ies or from the cross-reaction of antibodies with certain ir-
relevant antigens.20 Donors with indeterminate or positive 
anti-HIV/anti-HCV confirmatory results are directed to a 
healthcare facility for further evaluation and management, 
but unfortunately no feedback has been received about the 
definite clinical status of these cases. 
Although not recommended by the assay manufacturer 
company, another important point we want to emphasize 
from our study is the value of using a grey zone with posi-
tive threshold determination as a means of increasing the 
sensitivity of anti-HCV and anti-HIV screening tests. Posi-
Acar, Kemahli, Altunay et al.
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tive results were obtained in only 2 out of the 105 (1.9%) 
anti-HCV reactive samples that had fallen within the grey 
zone index (s/co value 0.70-0.99). For both samples, HCV 
RNA testing was performed simultaneously, however in 
both samples the results were found to be negative. In com-
parison, all confirmatory test results of the anti-HIV positive 
samples that were within the grey zone index value range 
were determined to be negative. In anti-HIV and anti-HCV 
EIA positive samples whose values were within the grey zone 
index (s/co 0.70-0.99), significantly more samples tested 
negative upon confirmation than those samples above the 
positive threshold value (s/co > 1.0). This suggests a con-
tradiction with regards to 2 issues, the first is the negative 
zone application requirement, the other is how to deal with 
donors whose test result is positive, but HCV RNA tests 
negative. In this case, it can be considered that the grey zone 
application is at least not required in anti-HIV screening 
tests. Nevertheless, further research is required to establish 
whether the grey zone application leads to unnecessary do-
nor loss and increase in costs. 
In conclusion, we believe that the decrease in HBV and 
HCV prevalence over time has been multifactorial and has 
been attributed to a higher public awareness compared to 
previous years as a result of intensive training and cam-
paigns, an increase in the volunteer donor numbers, more 
diligent donor questioning and examination, expansion of 
HBV vaccination coverage as well as confirmation of our 
screening results with sensitive confirmatory testing. While 
a decrease in HBV and HCV prevalence has been observed, 
the increase in HIV prevalence rate, despite similar trans-
mission routes, may be linked to a recent increased trend of 
HIV/AIDS cases observed in Turkey over the past few years. 
Another factor to consider with regards to HIV donor ques-
tioning is the fact that many donors still have reservations 
in answering questionnaires to the full extent out of fear 
that risk behaviour questions may somehow be used against 
them. We believe that the healthcare system would be better 
served by developing strategies with improved donor ques-
tioning that address the psychosocial aspects of HIV screen-
ing. We hope that the creation of these changes can mini-
mize the fear of social stigmata associated with HIV donor 
questioning while preserving donor confidentiality.
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